Senior Manager, Commercial Analytics

About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit’s core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit’s team is inspired to touch and help change lives through Summit’s clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA). Summit is headquartered in Miami, Florida, and has additional offices in California, New Jersey, the UK, and Ireland. Overview of Role: The Senior Manager, Commercial Analytics is the person who gets into the data and finds what is actually happening. This role mines the Company’s  internal commercial data and syndicated secondary data to produce insight the business can act on. Internal data means CRM activity, field reporting, specialty distributor and specialty pharmacy channel files, hub and patient services data, and the commercial data warehouse. Syndicated secondary data means purchased outlet level data, diagnosis and medical claims, patient-level longitudinal data, biomarker testing data, and oncology reference and affiliation data. The role sits below the Director, Commercial Analytics & Information and is the primary hands-on analyst for the function. Because ivonescimab is an intravenous, buy-and-bill product, standard prescription data will not describe demand. This role must build a credible picture of performance from purchase, claims, and channel data, and be explicit about what that picture can and cannot show. The successful candidate does not wait to be handed a question. They find the pattern, work out whether it matters commercially, and bring it forward with a point of view. Role and Responsibilities: Mine internal commercial data for insight, including CRM activity, field call and engagement data, specialty distributor and specialty pharmacy channel files, hub and patient services data, and the commercial data warehouse. Mine syndicated secondary data for insight, including outlet level purchase data, diagnosis and medical claims, patient-level longitudinal data, biomarker testing data, and prescriber and organization reference and affiliation data. Produce recurring performance analysis covering national, regional, and account level results, market share, and attainment against plan, and explain the drivers rather than only reporting the numbers. Analyze performance by customer segment, site of care, treatment setting, and treatment pattern, and identify where results diverge from expectation and why. Identify geographic variation in performance and translate it into specific, actionable recommendations for Sales Operations and the field. Build and maintain the analytical view of patient population, including biomarker testing and retesting rates, testing turnaround, treatment sequencing, and where eligible patients are being lost before treatment. Analyze the patient journey end to end, including referral and diagnosis, biomarker testing, treatment initiation, benefits verification and access, time to first infusion, persistence, and discontinuation. Analyze hub, patient services, and specialty pharmacy data to identify access and reimbursement friction and quantify the commercial impact of that friction. Support the customer targeting and segmentation approach with analysis of account potential, prescriber behavior, referral networks, and organizational affiliation, in partnership with Sales Operations and Marketing. Provide the analytical inputs to the commercial demand forecast, including patient segment sizing, treatment share trend analysis, and the historical basis behind assumptions. Build and maintain dashboards and self-service reporting in the business intelligence platform, designed for decisions rather than for data display. Proactively identify data anomalies, breaks, and quality problems in analytical output, investigate root cause, and escalate accordingly with a clear description of the impact. Document the definitions, logic, filters, and data sources behind every recurring analysis so another analyst can reproduce and audit the result. Analyze competitive performance and treatment landscape shifts in non-small cell lung cancer, and flag changes that carry commercial consequence. Synthesize secondary data findings with primary market research and field intelligence into a single explanation rather than three competing ones. Present findings to Commercial Operations, Sales, Marketing,